A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Cancer; Colorectal cancer; Glioblastoma; Lymphoma; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 17 Jan 2018 Planned End Date changed from 3 Apr 2018 to 1 Oct 2018.
- 20 Mar 2017 Planned End Date changed from 1 Apr 2017 to 3 Apr 2018.
- 15 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History